Inovio Pharmaceuticals Inc
INO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$116.72M
Close$
$0.74
48.3% downside
Current Fair Value
48.3% downsideOvervalued by 48.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $116.72 Million |
|---|---|
| Enterprise Value | $77.69 Million |
| Earnings per Share | $-1.81 |
| Beta | 1.71 |
| Outstanding Shares | 81,619,113 |
Return
| Return on Equity | 250367.48% |
|---|---|
| Return on Assets | -141232.78% |
| Return on Invested Capital | 295869.93% |
Valuation & Multiples
| P/E Ratio | -1.04 |
|---|---|
| PEG | -12.79 |
| Price to Sales | - |
| Price to Book Ratio | -1.43 |
| Enterprise Value to Revenue | 332.62 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -0.23 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 10, 2026
EPS
-$0.50
Est. -$0.21Revenue
$298,901
Est. $2.27 MNext Earnings Call
Expected Date
March 11, 2027
EPS Estimate
-$0.14
Consensus analyst estimateRevenue Estimate
$50,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 4.93% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.34%▼ 40.51% |
|---|---|
| Total Invested | $1.33M▼ 96.34% |
| Investors Holding | 25▼ 88.00% |
About Inovio Pharmaceuticals Inc
112 employees
CEO: Jong Kim
Inovio Pharmaceuticals, Inc. is a biotechnology firm focused on researching, developing, and bringing to market DNA-based treatments designed to address and safeguard individuals from conditions linked to human papillomavirus (HPV), vari...